文献速递心外重症与机械循环支持

诱导治疗对心脏移植死亡率和治疗性排斥反应的影响:一项回顾性研究

The impact of induction therapy on mortality and treated rejection in cardiac transplantation: A retrospective study.
PubMed 文献 · J Heart Lung Transplant · 2022-01-19

该回顾性研究分析UNOS数据库中2000至2017年34,361例成人心脏移植患者,比较T细胞清除剂(TC-DA)、IL2受体拮抗剂诱导与无诱导治疗对全因死亡率和1年治疗性排斥的影响;TC-DA诱导与1年治疗性排斥风险降低相关且不影响死亡率,IL2R拮抗剂与死亡率轻度但统计学显著升高相关且对排斥风险无影响。

要点

  • TC-DA诱导与1年治疗性排斥几率降低相关(OR 0.82,95%CI 0.76-0.88,p<0.001),对死亡率无影响(HR 0.98,95%CI 0.93-1.03,p=0.48)。
  • IL2R拮抗剂诱导与全因死亡率轻度但统计学显著升高相关(HR 1.06,95%CI 1.01-1.11,p=0.02),对1年治疗性排斥无显著影响(OR 1.03,95%CI 0.96-1.11,p=0.36)。
  • 52%的队列未接受任何诱导治疗,27%接受IL2R拮抗剂,其余接受TC-DA。

核心结论

  • 与无诱导治疗相比,TC-DA诱导与1年治疗性排斥风险降低相关且对死亡率无影响,IL2R拮抗剂与死亡率小幅但统计学显著升高相关且对排斥风险无影响。

研究设计与样本

  • 回顾性分析UNOS数据库中2000至2017年接受心脏移植的所有成人患者(年龄≥18岁),排除既往移植和双器官移植者,最终纳入34,361例。
  • 采用倾向性评分校正的Cox回归模型评估TC-DA、IL2R拮抗剂诱导与无诱导治疗的效应,主要结局为全因死亡率,次要结局为1年治疗性排斥(77%患者可获得)。

主要发现

  • 52%的队列未接受任何诱导治疗,27%接受IL2R拮抗剂,其余接受TC-DA;受者中位年龄55岁(IQR 46-62),25%为女性,39%在移植时接受左心室辅助装置支持。
  • 中位随访4.2年(IQR 1.1-8.5),32%报告死亡;25%的患者在1年时发生治疗性排斥。
  • 倾向性评分校正的多因素分析显示,TC-DA诱导对死亡率无影响(HR 0.98,95%CI 0.93-1.03,p=0.48),IL2R拮抗剂与全因死亡率风险轻度升高相关(HR 1.06,95%CI 1.01-1.11,p=0.02)。
  • TC-DA诱导与1年治疗性排斥几率降低相关(OR 0.82,95%CI 0.76-0.88,p<0.001),IL2R拮抗剂诱导对1年治疗性排斥无显著影响(OR 1.03,95%CI 0.96-1.11,p=0.36)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evidence regarding the utility of routine induction therapy on outcomes is not clear. This study aims to evaluate whether induction therapy is associated with a reduced risk of treated rejection and improved overall survival. METHODS: We retrospectively analyzed all adult patients (age ≥ 18 years) that are included in the UNOS database who underwent heart transplantation between 2000 and 2017. Patients with prior transplants and dual organ transplants were excluded. 34,361 patients were included in the final analysis. We assessed the impact of induction therapy with T cell depleting agents (TC-DA), IL2 receptor antagonists (IL2R antagonist) and compared that to no induction therapy using Cox regression models adjusted for propensity scores. The primary outcome measure was all-cause mortality, whereas treated rejection at one year was analyzed as a secondary outcome measure (available in 77% of patients). RESULTS: A total of 52% of the cohort did not receive any induction therapy. A total of 27% received IL2R antagonist and the rest received TC-DA. Median age of the recipients was 55 (IQR: 46-62) years. A total of 25% of the population were women and 39% were supported on left ventricular assist device therapy at the time of transplantation. Median follow-up was 4.2 (IQR: 1.1-8.5) years with 32% reported mortality. Multivariate analysis with propensity score adjustment showed that TC-DA induction did not have any effect on mortality (HR = 0.98, 95% CI 0.93-1.03, p = 0.48). However, IL2R antagonist was associated with a modestly increased risk of all-cause mortality compared to no induction (HR = 1.06, 95% CI 1.01-1.11, p = 0.02, respectively). A total of 25% of patients were found to have treated rejection at one year, TC-DA induction was associated with reduced odds of rejection at one year (OR = 0.82, 95% CI 0.76-0.88, p < 0.001). However, induction with IL2R antagonist was not found to have a significant impact (OR = 1.03, 95% CI 0.96-1.11, p = 0.36). CONCLUSIONS: Compared to no induction therapy, induction with TC-DA was associated with reduction in risk of treated rejection at 1 year with no effect on mortality and IL2R antagonist was associated with a small but statistically significant increase in mortality without any impact on risk of rejection.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Bellumkonda L, Oikonomou EK, Hsueh C, et al. The impact of induction therapy on mortality and treated rejection in cardiac transplantation: A retrospective study. J Heart Lung Transplant. 2022. PMID: 35094919. doi:10.1016/j.healun.2022.01.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。